表紙
市場調查報告書
商品編碼
974919

糖尿病監測設備市場:按設備類型(血糖自我監測設備,連續血糖監測設備),按糖尿病類型(1型糖尿病,2型糖尿病),按設備零件(血糖自我監測設備)

Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component

出版日期: | 出版商: Roots Analysis | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告分析了糖尿病血糖測量設備(血糖監測設備)的全球市場,並按設備類型,設備類型,設備零件和地區分析了市場的基本結構和最新情況。我們將為您提供有關市場趨勢展望(2020-2030年),主要商業聯盟和合作動態,主要公司概況,當前問題和未來市場機會的信息。

目錄

第1章簡介

第2章執行摘要

第3章簡介

  • 分析摘要
  • 糖尿病概述
    • 糖尿病分類
  • 與糖尿病監測有關的主要問題
  • 糖尿病監測裝置
    • 血糖自我監測裝置(SMBG)
    • 連續血糖監測裝置
  • 未來展望

第4章當前市場狀況

  • 分析摘要
  • 糖尿病監測儀:市場總體情況
    • 按設備類型分析
    • 按當前發展狀況進行分析
    • 按目標患者細分進行分析
    • 通過分析材料的採購方法進行分析
    • 按使用的分析目標量進行分析
    • 按處理速度分析
    • 穿著性別分析
    • 通過無線連接進行分析
    • 耐水性分析
    • 默認警報/警報分析
    • 按屬性分析設備內存
    • 通過測量範圍分析葡萄糖
  • 糖尿病監測裝置:開發商名單
    • 按開發公司類型分析
    • 成立年份分析
    • 按公司規模分析
    • 區域分析
    • 主要開發商:按產品數量分析

第5章產品競爭力分析

  • 分析摘要
  • 分析的先決條件和方法
    • 產品競爭力分析:糖尿病監測儀

第6章商業聯盟/合作

  • 分析摘要
  • 商業聯盟(夥伴關係)模型
  • 糖尿病監測設備:商業聯盟與合作清單
    • 按業務聯盟成立年份分的分析
    • 按業務聯盟類型分析
    • 按年份和類型分析業務聯盟
    • 按設備類型分析
    • 最活躍的公司:按業務聯盟數量分析
    • 區域分析

第7章公司簡介

  • 分析摘要
  • ApexBio
    • 公司簡介
    • 糖尿病監測設備組合
    • 最新趨勢和未來前景
  • Ascensia Diabetes Care
  • i-SENS
  • Oak Tree Health
  • SD Biosensor
  • TaiDoc Technology
  • VivaCheck Laboratories

第8章主要製藥公司:與糖尿病監測設備相關的業務發展狀況

  • 分析摘要
  • 範圍和分析方法
  • 主要製藥公司的業務發展狀況
    • 按類型分析疾病管理解決方案
    • 按糖尿病藥物數量分析(已銷售/正在調查中)
    • 按糖尿病類型分析
    • 按藥物類型分析
    • 按業務聯盟數量分析
  • 主要製藥公司的競爭基準
    • 雷達圖分析:A公司
    • 雷達圖分析:B公司
    • 雷達圖分析:C公司
    • 雷達圖分析:D公司
    • 雷達圖分析:E公司

第9章市場規模/機會分析

  • 分析摘要
  • 範圍和分析方法
  • 糖尿病監測設備市場:整體分析(2020-2030年)
  • 糖尿病監測設備市場:按設備類型分析(2020-2030)
  • 血糖自我監測設備市場:整體分析
    • 按糖尿病類型分(2020-2030)
    • 按設備/組件劃分(2020-2030)
    • 按地區(2020-2030)
  • 連續血糖監測儀市場:整體分析
    • 按糖尿病類型分(2020-2030)
    • 按設備/組件劃分(2020-2030)
    • 按地區(2020-2030)

第10章結論

第11章管理注意事項/意見站點

  • 分析摘要
  • Cambridge Consultants
    • 公司簡介
    • 採訪記錄
  • Know Labs

第12章附錄1:匯總數據

第13章附錄2:公司/組織列表

目錄

Title:
Diabetes Monitoring Devices Market
by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030.

Overview:

Diabetes is one of the seven leading causes of death and disability across the world. According to the World Health Organization (WHO), more than 1.6 million deaths are directly attributed to diabetes each year. In 2019, the global expenditure on diabetes treatment and disease management was estimated to be over USD 750 billion; this is indicative of the significant burden on patients and the global healthcare system. Timely glucose monitoring helps prevent unwanted glucose fluctuations (hyperglycemia / hypoglycemia) , which are known to have serious implications, including (but not limited to) kidney damage, cardiovascular complications, visual impairment, diabetic ketoacidosis and circulatory defects (some of which are known to progress to a stage requiring amputation) . The current gold standard for self-monitoring of blood glucose level involves the use glucose meters. These are compact devices designed to measure glucose levels in blood, which is typically extracted (using a small needle) from patients' fingertips or forearms. For adequate glycemic control, it is essential for diabetics to measure glucose levels multiple (3-4) times in a day; since the process involves the use of a needle, compliance is a primary concern. Moreover, there are several other concerns, such as inaccurate readings and needlestick injuries, associated with the use of conventional glucose monitoring devices.

Over time, a number of companies have developed advanced variants of the conventional blood glucose monitors that are portable, and minimally- / non-invasive. Many such next generation solutions have connectivity features, which enable patients' health data to be captured and shared with medical professionals, upon request. In addition, there are a number of innovative continuous glucose monitoring (CGM) systems, which are designed to provide real-time insights on blood glucose levels. Newer variants of these products are now chockful of intuitive software that enables patients to quickly make important treatment-related decisions. This field is presently the epicenter of innovation in the diabetes market; a popular example is the artificial pancreas, which is basically a combination of a CGM system and a large volume wearable injector, powered by intuitive algorithms that drive the delivery of insulin and glucagon. The diabetes monitoring devices market is anticipated to witness steady growth, largely driven by the increasing diabetic patient population and the introduction of advanced and cost effective solutions, in the coming years.

Scope of the Report:

The "Diabetes Monitoring Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes monitoring devices, over the next decade. The study also features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • An overview of current market landscape of the diabetes monitoring devices, providing information on device specifications, such as type of device (self-monitoring blood glucose device and continuous blood glucose monitoring devices), current status of development (preclinical, clinical and marketed), target patient segment (children, adults and elderly patients), analyte procurement (invasive, non-invasive and minimally invasive), volume of analyte used (less than 0.8 μL, 0.8 to 2 μL and more than 2 μL), processing speed (fast and slow), wearability (wearable and non-wearable), wireless connectivity, water resistance potential, provision for alerts / alarms, device memory attributes and glucose measurement range. In addition, the report presents the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size, location of headquarters and leading developers.
  • A detailed competitiveness analysis of diabetes monitoring devices, taking into consideration the supplier power (based on the experience / expertise of the developer) and product specifications (type of device, current status of development, target patient segment, analyte procurement, volume of analyte used, processing speed, wireless connectivity, water resistance potential, provision for alerts / alarms and device memory attributes) .
  • An analysis of the partnerships that have been inked by the stakeholders in this domain, during the period between 2015 and 2020 (till August) , covering product / technology integration agreements, commercialization agreements, distribution agreements, product development agreements, acquisitions, product development and commercialization agreements and other relevant types of deals.
  • Elaborate profiles of prominent companies that develop diabetes monitoring devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
  • A review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 5 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes monitoring devices. Based on multiple parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features sales forecasts for the overall diabetes monitoring devices market with a detailed market segmentation on the [A] type of device (self-monitoring blood glucose device and continuous blood glucose monitoring device), [B] diabetes type (type 1 diabetes and type 2 diabetes), [C] device component (self-monitoring blood glucose devices: lancing device, blood glucose meter and testing strips; continuous glucose monitoring devices: sensors, transmitter and receiver) and [D] key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

Key Questions Answered:

  • Which are the leading diabetes monitoring device developers?
  • What are the popular monitoring devices currently being marketed / developed in this domain?
  • What novel / advanced features are device developers focusing on to maintain a competitive edge in the market?
  • What kind of partnership models are commonly adopted by stakeholders in this industry?
  • What initiatives big pharma companies have taken to expand their existing capabilities and comply with industry benchmarks?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the diabetes monitoring devices market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to diabetes and a discussion on the various existing challenges in diabetes monitoring. Additionally, it features brief descriptions of various diabetes monitoring devices and concludes with a discussion on the future trends that are likely to impact this emerging market segment.

Chapter 4 includes an assessment of current market landscape of the diabetes monitoring devices, based on various parameters, such as type of device (self-monitoring blood glucose device and continuous blood glucose monitoring devices), current status of development (preclinical, clinical and marketed), target patient segment (children, adults and elderly patients), analyte procurement (invasive, non-invasive and minimally invasive), volume of analyte used (less than 0.8 μL, 0.8 to 2 μL and more than 2 μL), processing speed (fast and slow), wearability (wearable and non-wearable), wireless connectivity, water resistance potential, provision for alerts / alarms, device memory attributes and glucose measurement range. In addition, the report presents the details of the companies developing these devices, including information on type of developer (industry and non-industry), year of establishment, company size, location of headquarters and leading developers.

Chapter 5 presents a detailed competitiveness analysis of diabetes monitoring devices based on various relevant parameters, such as supplier power (based on the experience / expertise of the developer) and product specifications (type of device, current status of development, target patient segment, analyte procurement, volume of analyte used, processing speed, wireless connectivity, water resistance potential, provision for alerts / alarms and device memory attributes) .

Chapter 6 features an analysis of the various partnerships and collaborations that have been inked amongst players in this domain, in the time period 2015-2020 (till August). It provides a brief description on the various types of partnership models (product / technology integration agreements, commercialization agreements, distribution agreements, product development agreements, acquisitions, product development and commercialization agreements and other relevant types of deals) that have been adopted by stakeholders in this domain. Further, it includes analyses based on year of partnership, type of partnership, type of device mentioned in the agreement and most active players. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 7 provides detailed profiles of the prominent companies that develop diabetes monitoring devices. Each company profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.

Chapter 8 provides a review of recent initiatives undertaken by big pharma players in this domain. It also features a benchmark analysis of top 10 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as diversity of device portfolio number of marketed diabetes and clinical-stage diabetes drugs, diabetes type, type of diabetes drug evaluated and partnerships.

Chapter 9 presents an insightful market forecast analysis, highlighting the future potential of diabetes monitoring devices till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of device (self-monitoring blood glucose device and continuous glucose monitoring device), [B] diabetes type (type 1 diabetes and type 2 diabetes), [C] device component (self-monitoring blood glucose devices: glucose meters, test strips and lancets; continuous glucose monitoring devices: sensors, transmitters and receivers) and [D] key geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and rest of the world).

Chapter 10 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the diabetes monitoring devices market.

Chapter 11 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Ambuj Jain (General Manager-Business Development, Cambridge Consultants), Ron Erickson (Founder and Chairman, Know Labs)

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Diabetes
    • 3.2.1. Classification of Diabetes
      • 3.2.1.1. Type 1 Diabetes
      • 3.2.1.2. Type 2 Diabetes
      • 3.2.1.3. Gestational Diabetes
  • 3.3. Key Challenges Associated with Diabetes Monitoring
  • 3.4. Diabetes Monitoring Devices
    • 3.4.1. Devices for Self-Monitoring of Blood Glucose Levels
      • 3.4.1.1. Blood Glucose Meter
      • 3.4.1.2. Testing Strips
      • 3.4.1.3. Lancets
    • 3.4.2. Continuous Blood Glucose Monitoring Devices
      • 3.4.2.1. Sensors
      • 3.4.2.2. Transmitters
      • 3.4.2.3. Receivers
      • 3.4.2.4. Patches
  • 3.5. Future Perspectives

4. CURRENT MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Diabetes Monitoring Devices: Overall Market Landscape
    • 4.2.1. Analysis by Type of Device
    • 4.2.2. Analysis by Current Status of Development
    • 4.2.3. Analysis by Target Patient Segment
    • 4.2.4. Analysis by Analyte Procurement
    • 4.2.5. Analysis by Volume of Analyte Used
    • 4.2.6. Analysis by Processing Speed
    • 4.2.7. Analysis by Wearability
    • 4.2.8. Analysis by Wireless Connectivity
    • 4.2.9. Analysis by Water Resistance Potential
    • 4.2.10. Analysis by Provisions for Alerts / Alarms
    • 4.2.11. Analysis by Device Memory Attributes
    • 4.2.12. Analysis by Glucose Measurement Range
  • 4.3. Diabetes Monitoring Devices: List of Developers
    • 4.3.1. Analysis by Type of Developer
    • 4.3.2. Analysis by Year of Establishment
    • 4.3.3. Analysis by Company Size
    • 4.3.4. Analysis by Geographical Location
    • 4.3.5. Leading Developers: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Methodology
    • 5.2.1. Product Competitiveness Analysis: Diabetes Monitoring Devices
      • 5.2.1.1. Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices
      • 5.2.1.2. Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices

6. PARTNERSHIPS AND COLLABORATIONS

  • 6.1. Chapter Overview
  • 6.2. Partnership Models
  • 6.3. Diabetes Monitoring Devices: List of Partnerships and Collaborations
    • 6.3.1. Analysis by Year of Partnership
    • 6.3.2. Analysis by Type of Partnership
    • 6.3.3. Analysis by Year and Type of Partnership
    • 6.3.4. Analysis by Type of Device
    • 6.3.5. Most Active Players: Analysis by Number of Partnerships
    • 6.3.6. Geographical Analysis
      • 6.3.6.1. Region-wise Distribution
      • 6.3.6.2. Country-wise Distribution

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. ApexBio
    • 7.2.1. Company Overview
    • 7.2.2. Diabetes Monitoring Devices Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Ascensia Diabetes Care
    • 7.3.1. Company Overview
    • 7.3.2. Diabetes Monitoring Devices Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. i-SENS
    • 7.4.1. Company Overview
    • 7.4.2. Diabetes Monitoring Devices Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Oak Tree Health
    • 7.5.1. Company Overview
    • 7.5.2. Diabetes Monitoring Devices Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. SD Biosensor
    • 7.6.1. Company Overview
    • 7.6.2. Diabetes Monitoring Devices Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. TaiDoc Technology
    • 7.7.1. Company Overview
    • 7.7.2. Diabetes Monitoring Devices Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. VivaCheck Laboratories
    • 7.8.1. Company Overview
    • 7.8.2. Diabetes Monitoring Devices Portfolio
    • 7.8.3. Recent Developments and Future Outlook

8. DIABETES MONITORING DEVICES RELATED INITIATIVES OF BIG PHARMA PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Initiatives of Big Pharma Players
    • 8.3.1. Analysis by Type of Disease Management Solution
    • 8.3.2. Analysis by Number of Marketed and Clinical-Stage Diabetes Drugs
    • 8.3.3. Analysis by Diabetes Type
    • 8.3.4. Analysis by Type of Drug
    • 8.3.5. Analysis by Number of Partnerships
  • 8.4. Competitive Benchmarking of Big Pharma Players
    • 8.4.1. Spider Web Analysis: Company A
    • 8.4.2. Spider Web Analysis: Company B
    • 8.4.3. Spider Web Analysis: Company C
    • 8.4.4. Spider Web Analysis: Company D
    • 8.4.5. Spider Web Analysis: Company E

9. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology and Assumptions
  • 9.3. Overall Diabetes Monitoring Devices Market, 2020-2030
  • 9.4. Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device
  • 9.5. Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030
    • 9.5.1. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type
    • 9.5.2. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component
    • 9.5.3. Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution
      • 9.5.3.1. Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030
      • 9.5.3.2. Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030
      • 9.5.3.3. Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030
      • 9.5.3.4. Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030
      • 9.5.3.5. Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030
      • 9.5.3.6. Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030
  • 9.6. Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030
    • 9.6.1. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type
    • 9.6.2. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component
    • 9.6.3. Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution
      • 9.6.3.1. Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030
      • 9.6.3.2. Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030
      • 9.6.3.3. Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030
      • 9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030
      • 9.6.3.4. Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030
      • 9.6.3.6. Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030

10. CONCLUDING REMARKS

  • 10.1. Chapter Overview
  • 10.2. Key Takeaways

11. EXECUTIVE INSIGHTS

  • 11.1. Chapter Overview
  • 11.2. Cambridge Consultants
    • 11.2.1. Company Snapshot
    • 11.2.2. Interview Transcript: Ambuj Jain, General Manager- Business Development
  • 11.3. Know Labs
    • 11.3.1. Company Snapshot
    • 11.3.2. Interview Transcript: Ron Erickson, Founder and Chairman

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 4.1 Diabetes Monitoring Devices: Distribution by Type of Device
  • Figure 4.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
  • Figure 4.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
  • Figure 4.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
  • Figure 4.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
  • Figure 4.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
  • Figure 4.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
  • Figure 4.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
  • Figure 4.9 Diabetes Monitoring Devices: Distribution by Processing Speed
  • Figure 4.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
  • Figure 4.11 Diabetes Monitoring Devices: Distribution by Wearability
  • Figure 4.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
  • Figure 4.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
  • Figure 4.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
  • Figure 4.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
  • Figure 4.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
  • Figure 4.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
  • Figure 4.18 Diabetes Monitoring Devices: Distribution by Device Memory Attributes
  • Figure 4.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
  • Figure 4.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
  • Figure 4.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
  • Figure 4.22 Diabetes Monitoring Device Developers: Distribution by Company Size
  • Figure 4.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
  • Figure 4.24 Leading Developers: Analysis by Number of Products
  • Figure 5.1 Continuous Blood Glucose Monitoring Devices: Dot Plot Analysis
  • Figure 5.2 Product Competitiveness Analysis: Continuous Blood Glucose Monitoring Devices
  • Figure 5.3 Self-Monitoring Blood Glucose Devices: Dot Plot Analysis
  • Figure 5.4 Product Competitiveness Analysis: Self-Monitoring Blood Glucose Devices
  • Figure 6.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 6.4 Partnerships and Collaborations: Distribution by Type of Device
  • Figure 6.5 Most Active Players: Analysis by Number of Partnerships
  • Figure 6.6 Partnerships and Collaborations: Region-wise Distribution
  • Figure 6.7 Partnerships and Collaborations: Country-wise Distribution
  • Figure 8.1 Big Pharma Initiatives: Heat Map Analysis of Top Pharmaceutical Companies
  • Figure 8.2 Big Pharma Initiatives: Distribution by Type of Disease Management Solution
  • Figure 8.3 Big Pharma Initiatives: Distribution by Number of Marketed and Clinical-Stage Diabetes Drugs
  • Figure 8.4 Big Pharma Initiatives: Distribution by Diabetes Type
  • Figure 8.5 Big Pharma Initiatives: Distribution by Type of Drug
  • Figure 8.6 Big Pharma Initiatives: Distribution by Number of Partnerships
  • Figure 8.7 Spider Web Analysis: Company A
  • Figure 8.8 Spider Web Analysis: Company B
  • Figure 8.9 Spider Web Analysis: Company C
  • Figure 8.10 Spider Web Analysis: Company D
  • Figure 8.11 Spider Web Analysis: Company E
  • Figure 9.1 Overall Diabetes Monitoring Devices Market, 2020-2030 (USD Billion)
  • Figure 9.2 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
  • Figure 9.3 Overall Self-Monitoring Blood Glucose Devices Market, 2020-2030 (USD Billion)
  • Figure 9.4 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
  • Figure 9.5 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
  • Figure 9.6 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
  • Figure 9.7 Self-Monitoring Blood Glucose Devices Market in North America, 2020-2030 (USD Billion)
  • Figure 9.8 Self-Monitoring Blood Glucose Devices Market in Europe, 2020-2030 (USD Billion)
  • Figure 9.9 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, 2020-2030 (USD Billion)
  • Figure 9.10 Self-Monitoring Blood Glucose Devices Market in Latin America, 2020-2030 (USD Billion)
  • Figure 9.11 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Figure 9.12 Self-Monitoring Blood Glucose Devices Market in Rest of the World, 2020-2030 (USD Billion)
  • Figure 9.13 Overall Continuous Blood Glucose Monitoring Devices Market, 2020-2030 (USD Billion)
  • Figure 9.14 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
  • Figure 9.15 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
  • Figure 9.16 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
  • Figure 9.17 Continuous Blood Glucose Monitoring Devices Market in North America, 2020-2030 (USD Billion)
  • Figure 9.18 Continuous Blood Glucose Monitoring Devices Market in Europe, 2020-2030 (USD Billion)
  • Figure 9.19 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, 2020-2030 (USD Billion)
  • Figure 9.20 Continuous Blood Glucose Monitoring Devices Market in Latin America, 2020-2030 (USD Billion)
  • Figure 9.21 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Figure 9.22 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, 2020-2030 (USD Billion)
  • Figure 10.1 Diabetes Monitoring Device Market: Concluding Remarks

List Of Tables

  • Table 3.1 Blood Sugar Levels in Diabetic Patients
  • Table 3.2 Difference between Self-Monitoring and Continuous Monitoring Devices
  • Table 3.3 Glucose Monitoring Times and Frequency
  • Table 4.1 List of Diabetes Monitoring Devices
  • Table 4.2 Diabetes Monitoring Devices: List of Developers
  • Table 6.1 Diabetes Monitoring Devices: List of Partnerships, 2015-2020 (Till August)
  • Table 7.1 Leading Diabetes Monitoring Device Developers
  • Table 7.2 ApexBio: Company Overview
  • Table 7.3 ApexBio: Diabetes Monitoring Devices
  • Table 7.4 Ascensia Diabetes Care: Company Overview
  • Table 7.5 Ascensia Diabetes Care: Diabetes Monitoring Devices
  • Table 7.6 Ascensia Diabetes Care: Recent Developments and Future Outlook
  • Table 7.7 i-SENS: Company Overview
  • Table 7.8 i-SENS: Diabetes Monitoring Devices
  • Table 7.9 i-SENS: Recent Developments and Future Outlook
  • Table 7.10 Oak Tree Health: Company Overview
  • Table 7.11 Oak Tree Health: Diabetes Monitoring Devices
  • Table 7.12 SD Biosensor: Company Overview
  • Table 7.13 SD Biosensor: Diabetes Monitoring Devices
  • Table 7.14 SD Biosensor: Recent Developments and Future Outlook
  • Table 7.15 TaiDoc Technology: Company Overview
  • Table 7.16 TaiDoc Technology: Diabetes Monitoring Devices
  • Table 7.17 VivaChek Laboratories: Company Overview
  • Table 7.18 VivaChek Laboratories: Diabetes Monitoring Devices
  • Table 7.19 VivaChek Laboratories: Recent Developments and Future Outlook
  • Table 8.1 Top Big Pharma Players in Diabetes Domain
  • Table 8.2 Big Pharma Players: Spider-Web Analysis (Input Data)
  • Table 11.1 Cambridge Consultants: Company Snapshot
  • Table 11.2 Know Labs: Company Snapshot
  • Table 12.1 Diabetes Monitoring Devices: Distribution by Type of Device
  • Table 12.2 Diabetes Monitoring Devices: Distribution by Current Status of Development
  • Table 12.3 Diabetes Monitoring Devices: Distribution by Type of Device and Current Status of Development
  • Table 12.4 Diabetes Monitoring Devices: Distribution by Target Patient Segment
  • Table 12.5 Diabetes Monitoring Devices: Distribution by Type of Device and Target Patient Segment
  • Table 12.6 Diabetes Monitoring Devices: Distribution by Analyte Procurement
  • Table 12.7 Diabetes Monitoring Devices: Distribution by Type of Device and Analyte Procurement
  • Table 12.8 Diabetes Monitoring Devices: Distribution by Volume of Analyte Used
  • Table 12.9 Diabetes Monitoring Devices: Distribution by Processing Speed
  • Table 12.10 Diabetes Monitoring Devices: Distribution by Type of Device and Processing Speed
  • Table 12.11 Diabetes Monitoring Devices: Distribution by Wearability
  • Table 12.12 Diabetes Monitoring Devices: Distribution by Wireless Connectivity
  • Table 12.13 Diabetes Monitoring Devices: Distribution by Type of Device and Wireless Connectivity
  • Table 12.14 Diabetes Monitoring Devices: Distribution by Water Resistance Potential
  • Table 12.15 Diabetes Monitoring Devices: Distribution by Type of Device and Water Resistance Potential
  • Table 12.16 Diabetes Monitoring Devices: Distribution by Provisions for Alerts / Alarms
  • Table 12.17 Diabetes Monitoring Devices: Distribution by Type of Device and Provisions for Alerts / Alarms
  • Table 12.18 Diabetes Monitoring Devices: Distribution by Distribution by Device Memory Attributes
  • Table 12.19 Diabetes Monitoring Devices: Distribution by Glucose Measurement Range
  • Table 12.20 Diabetes Monitoring Device Developers: Distribution by Type of Stakeholder
  • Table 12.21 Diabetes Monitoring Device Developers: Distribution by Year of Establishment
  • Table 12.22 Diabetes Monitoring Device Developers: Distribution by Company Size
  • Table 12.23 Diabetes Monitoring Device Developers: Geographical Distribution by Location of Headquarters
  • Table 12.24 Leading Developers: Analysis by Number of Products
  • Table 12.25 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 12.26 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 12.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 12.28 Partnerships and Collaborations: Distribution by Type of Device
  • Table 12.29 Most Active Players: Analysis by Number of Partnerships
  • Table 12.30 Partnerships and Collaborations: Region-wise Distribution
  • Table 12.31 Partnerships and Collaborations: Country-wise Distribution
  • Table 12.32 Overall Diabetes Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.33 Diabetes Monitoring Devices Market, 2020-2030: Distribution by Type of Device (USD Billion)
  • Table 12.34 Overall Self-Monitoring Blood Glucose Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.35 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
  • Table 12.36 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
  • Table 12.37 Self-Monitoring Blood Glucose Devices Market, 2020-2030: Geographical Distribution (USD Billion)
  • Table 12.38 Self-Monitoring Blood Glucose Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.39 Self-Monitoring Blood Glucose Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.40 Self-Monitoring Blood Glucose Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.41 Self-Monitoring Blood Glucose Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.42 Self-Monitoring Blood Glucose Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.43 Self-Monitoring Blood Glucose Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.44 Overall Continuous Blood Glucose Monitoring Devices Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.45 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Diabetes Type (USD Billion)
  • Table 12.46 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Distribution by Device Component (USD Billion)
  • Table 12.47 Continuous Blood Glucose Monitoring Devices Market, 2020-2030: Geographical Distribution (USD Billion)
  • Table 12.48 Continuous Blood Glucose Monitoring Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.49 Continuous Blood Glucose Monitoring Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.50 Continuous Blood Glucose Monitoring Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.51 Continuous Blood Glucose Monitoring Devices Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 12.52 Continuous Blood Glucose Monitoring Devices Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion
  • Table 12.53 Continuous Blood Glucose Monitoring Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)

List Of Company

The following companies and organizations have been mentioned in the report.

  • 1. Abbott
  • 2. ABOX
  • 3. ACON Laboratories
  • 4. AgaMatrix
  • 5. AlDanah Medical
  • 6. Alertgy
  • 7. APExBIO
  • 8. Apple
  • 9. Arcadia Group
  • 10. ArKl Medical
  • 11. ARKRAY
  • 12. Ascensia Diabetes Care
  • 13. BeatO
  • 14. Beurer
  • 15. Bigfoot Biomedical
  • 16. Biolinq
  • 17. Blue Cross and Blue Shield of Minnesota
  • 18. Bruno Farmaceutici
  • 19. BTNX
  • 20. CEI Technology
  • 21. Cellnovo Group
  • 22. Chemglass Life Sciences
  • 23. CnogaCare
  • 24. Companion Medical
  • 25. Control D
  • 26. CuraTec Nordic
  • 27. Current Health
  • 28. Dallas Burston Ethitronix
  • 29. DarioHealth
  • 30. Debiotech
  • 31. Dexcom
  • 32. Diabeto
  • 33. DiaMonTech
  • 34. Diasend
  • 35. Diathrive
  • 36. DKSH
  • 37. Dnurse Technology
  • 38. Echo Therapeutics
  • 39. Eli Lilly
  • 40. EPS Biotechnology
  • 41. Essenlife Bioscience
  • 42. Fitbit
  • 43. Fleming Medical
  • 44. ForaCare
  • 45. Fudakang Industrial
  • 46. GE Healthcare
  • 47. Glooko
  • 48. GlucoRx
  • 49. Glucosense Diagnostics
  • 50. Glucovation
  • 51. Gluco-Z
  • 52. GluSense
  • 53. GlySens
  • 54. GlySure
  • 55. Glytec
  • 56. GraphWear Technologies
  • 57. Guangzhou Guang Yuan Biological Pharmaceutical
  • 58. Hangzhou Sejoy Electronics & Instruments
  • 59. Health Alliance Plan
  • 60. Health2Sync
  • 61. Hello Heart
  • 62. Henry Schein Medical
  • 63. HoyHealth
  • 64. IBM
  • 65. Indigo
  • 66. Infinovo Medical
  • 67. Inside Biometrics
  • 68. Insulet
  • 69. Integrated Medical Sensors
  • 70. Integrity Applications
  • 71. i-SENS
  • 72. JDRF
  • 73. Keto-Mojo
  • 74. Klue
  • 75. Know Labs
  • 76. KTH Royal Institute of Technology
  • 77. LG Life Sciences
  • 78. LifeCaring Technologies
  • 79. LifePlus
  • 80. LifeScan
  • 81. Livongo Health
  • 82. MediReva
  • 83. MediVena
  • 84. Medtronic
  • 85. Medtrum Technologies
  • 86. META
  • 87. Metronom Health
  • 88. Millennium Medical Supplies
  • 89. Morepen Laboratories
  • 90. National Diagnostic Products
  • 91. Nemaura Medical
  • 92. NovioSense
  • 93. Novo Nordisk
  • 94. Nutrino Health (acquired by Medtronic)
  • 95. Oak Tree Health
  • 96. OK Biotech
  • 97. Omada Health
  • 98. One Drop
  • 99. Pacific Diabetes Technologies
  • 100. Palmdoc
  • 101. PercuSense
  • 102. Pinnacle Technology
  • 103. PKvitality
  • 104. POCTech
  • 105. Prediktor Medical
  • 106. Prodigy Diabetes Care
  • 107. Qualcomm Life
  • 108. Quattro Folia
  • 109. Roche
  • 110. Rubin Medical
  • 111. SanaVita Medical
  • 112. Sano Intelligence
  • 113. Sanofi
  • 114. Sanvita Medical
  • 115. SD BIOSENSOR
  • 116. Senseonics
  • 117. SFC Fluidics
  • 118. Shezhen Jiacom Technology
  • 119. Smart Meter
  • 120. Spirit Health
  • 121. TaiDoc Technology
  • 122. Tandem Diabetes Care
  • 123. Terumo Medical
  • 124. Tianjin HUAC Healthcare Technology
  • 125. Tidepool
  • 126. TPMENA
  • 127. Trividia Health
  • 128. University of Bath
  • 129. University of California
  • 130. Validic
  • 131. Verily Life Sciences
  • 132. VivaChek Laboratories
  • 133. Voluntis
  • 134. Welldoc
  • 135. Xuzhou Yongkang Electronic Science Technology
  • 136. Ypsomed